Hikma Pharmaceuticals PLC (LSE:HIK) — Market Cap & Net Worth
Market Cap & Net Worth: Hikma Pharmaceuticals PLC (HIK)
Hikma Pharmaceuticals PLC (LSE:HIK) has a market capitalization of $39.53 Million (GBX324.87 Billion) as of June 17, 2026. Listed on the LSE stock exchange, this UK-based company holds position #22821 globally and #184 in its home market, demonstrating a 0.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hikma Pharmaceuticals PLC's stock price GBX1467.00 by its total outstanding shares 221451926 (221.45 Million). Review Hikma Pharmaceuticals PLC total liabilities to assess the company's total debt and financial obligations.
Hikma Pharmaceuticals PLC Market Cap History: 2015 to 2026
Hikma Pharmaceuticals PLC's market capitalization history from 2015 to 2026. Data shows change from $49.47 Million to $39.53 Million (-1.26% CAGR).
Index Memberships
Hikma Pharmaceuticals PLC is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$68.02 Billion | 0.06% | #123 of 573 |
|
FTSE 350
FTLC
|
$67.62 Billion | 0.06% | #120 of 350 |
|
STOXX Europe Mid 200 EUR Price
MCXP
|
$1.48 Trillion | 0.00% | #127 of 157 |
|
STOXX Europe Mid 200 EUR Net Return
MCXR
|
$1.48 Trillion | 0.00% | #127 of 157 |
|
FTSE 350 Pharmaceuticals & Biotechnology
NMX4570
|
$3.54 Billion | 1.12% | #3 of 6 |
Weight: Hikma Pharmaceuticals PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hikma Pharmaceuticals PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hikma Pharmaceuticals PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Hikma Pharmaceuticals PLC's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.15x
Hikma Pharmaceuticals PLC's market cap is 0.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $49.47 Million | $1.44 Billion | $252.00 Million | 0.03x | 0.20x |
| 2016 | $41.14 Million | $1.95 Billion | $155.00 Million | 0.02x | 0.27x |
| 2017 | $25.10 Million | $1.94 Billion | -$843.00 Million | 0.01x | N/A |
| 2018 | $38.96 Million | $2.07 Billion | $282.00 Million | 0.02x | 0.14x |
| 2019 | $46.18 Million | $2.21 Billion | $486.00 Million | 0.02x | 0.10x |
| 2020 | $59.81 Million | $2.34 Billion | $431.00 Million | 0.03x | 0.14x |
| 2021 | $53.90 Million | $2.55 Billion | $421.00 Million | 0.02x | 0.13x |
| 2022 | $38.87 Million | $2.52 Billion | $188.00 Million | 0.02x | 0.21x |
| 2023 | $46.32 Million | $2.88 Billion | $190.00 Million | 0.02x | 0.24x |
| 2024 | $53.70 Million | $3.13 Billion | $359.00 Million | 0.02x | 0.15x |
Competitor Companies of HIK by Market Capitalization
Companies near Hikma Pharmaceuticals PLC in the global market cap rankings as of June 17, 2026.
Key companies related to Hikma Pharmaceuticals PLC by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Hikma Pharmaceuticals PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Hikma Pharmaceuticals PLC's market cap moved from $49.47 Million to $ 39.53 Million, with a yearly change of -1.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX39.53 Million | -5.35% |
| 2025 | GBX41.76 Million | -22.23% |
| 2024 | GBX53.70 Million | +15.93% |
| 2023 | GBX46.32 Million | +19.18% |
| 2022 | GBX38.87 Million | -27.90% |
| 2021 | GBX53.90 Million | -9.87% |
| 2020 | GBX59.81 Million | +29.51% |
| 2019 | GBX46.18 Million | +18.52% |
| 2018 | GBX38.96 Million | +55.21% |
| 2017 | GBX25.10 Million | -38.99% |
| 2016 | GBX41.14 Million | -16.83% |
| 2015 | GBX49.47 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Hikma Pharmaceuticals PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $39.53 Million USD |
| MoneyControl | $39.53 Million USD |
| MarketWatch | $39.53 Million USD |
| marketcap.company | $39.53 Million USD |
| Reuters | $39.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more